The CLARITY trial looks at the impact of COVID-19 on people with Crohn’s and Colitis who are taking either infliximab or vedolizumab.
New research looks at the link between Crohn’s and Colitis medications and the coronavirus vaccine. The CLARITY trial is looking at the impact of coronavirus on people with Crohn’s and Colitis who are taking either infliximab or vedolizumab.
We learned there is no evidence that people taking infliximab or vedolizumab are more likely to catch coronavirus, or have more serious illness from coronavirus. And both people taking infliximab and vedolizumab made a good antibody response after two vaccine doses. However, the research raises the need for more investigation, such as when people with a weakened immune system should receive their second vaccination.
This study shows the importance of ongoing research into the relationship between Crohn’s, Colitis and coronavirus. It’s a complex issue and may mean that the current vaccination system needs to adapt for people on specific types of medication which are commonly used in conditions such as Crohn’s and Colitis. The good news is that after a second dose people on both infliximab and vedolizumab produce a good antibody response. And we’re speaking with government to get this issue on the agenda.